ZD7288 hydrate, > = 98% (HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

ZD7288 hydrate has been used asI_hblocker to study its effect on neocortical tissue. It has been used as hyperpolarization-activated and cyclic nucleotide-gated (HCN)-channel blocker to test the involvement of HCN channels in the phototransduction pathway.

Biochem/physiol Actions

ZD7288 can block hippocampal synaptic plasticity.

Selective blocker of cation channel Ih; If blocker and sino-atrial node function modulator, blocks hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Cyclic Nucleotide-Gated (CNG) and Hyperpolarization Activated Cyclic Nucleotide-Gated (HCN) Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle